Clinical Trial Update: A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) [Phase 1]

View source ↗

Summary

A Phase 1, open-label, non-randomized multicenter dose-escalation study to assess safety and tolerability of OPB-111077 in subjects with advanced hepatocellular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OPB-111077

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED